Tolerability assessment of maximal androgen blockade with 50 mg daily of bicalutamide and castration in patients with advanced prostate cancer

Chang Gung Medical Journal

Volumn 25, Issue 9, 2002, Pages 577-582

  Chuang, Cheng Keng ^a,b   Chu, Sheng Hsien ^a   Chiang, Yang Jen ^a   Wu, Chun Te ^a   Lin, Mei Hsiu ^a   Wei, Tsuei Yuan ^a   Lin, Su Jeng ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antiandrogen; Maximal androgen blockade; Prostate; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GOSERELIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFECT; DRUG TOLERABILITY; GYNECOMASTIA; HORMONAL REGULATION; HOT FLUSH; HUMAN; LEG EDEMA; MALE; ORCHIECTOMY; PATIENT COMPLIANCE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QUALITY OF LIFE; RASH; SWEATING; THORAX PAIN; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0036760231     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hsing AW, Tsao L, Devesa SS. International trends in prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
2. National Cancer Institute, SEER Program, USA, 2000.
3. Cancer Registry, Republic of China, 2002.
4. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Seminars in Surgical Oncology 2000;18:52-74.
5. Newling DW. Clinical assessment and management of stage T3 prostate cancer. European Urology 1997;32:55-9.
6. Schroder FH. Endocrine treatment of prostate cancer-recent developments and the future. Part I: Maximal androgen blockade, early vs. delayed endocrine treatment and side effects. BJU International 1999;83:161-70.
7. Denis LJ. Maximal androgen blockade in prostate cancer: A theory put into practice. Prostate 1996;29:194.
8. Kirby RS. Maximal androgen blockade (MAB) for the treatment of prostate cancer. Br J Clin Practice 1996;50:287.
9. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Eng J Med 1989;321:419-24
10. Denis LJ, Carnelo de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchidectomy. A Phase III EORTC trial (30853). Urology 1993;42:119-30.
11. Janknegt RA, Abbou CC, Barteletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-82.
12. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP, Sotarauta M. Multicenter randomized trial companying Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Cancer 1993;72:3878-9.
13. Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur. J Cancer 1993;29:1088-93.
14. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996;47:54-60.
15. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urology 1979;17:159-63.
16. Wu CT, Chuang CK, Chou CC, Chu SH, Chen HW, Chen CS, Chiang YJ, Liao SK. The role of free to total prostate-specific antigen in prostate cancer screening for patients with total serum level between 4 and 20 ng/ml. Chang Gung Med J 2000;23:142-8.
17. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM. Use of human prostate specific antigen in monitoring prostate cancer. Cancer Res 1981;41:3874-6.
18. Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985;45:886-91.
19. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989;141:1088-90.
20. Matzkin H, Eber P, Todd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992;70:2302-9.
21. Blackledge GR, Lowery K. Role of prostatic-specific antigen as a predictor of outcome in prostate cancer. Prostate 1994;5:34-8.